uniQure’s Huntington’s Gene Therapy Shows 80% Slowing of Disease…

Event summary

uniQure’s ifezuntirgene inilparvovec (AMT-130) showed 80% slowing of disease progression in Huntington’s patients at 36 months, per updated Phase I/II data.
48-month data showed 44% slowing in cUHDRS (non-significant) but 61% slowing in TFC (p=0.008), with post-hoc analysis suggesting 54% and 68% slowing respectively.
High-dose patients demonstrated a dose-dependent treatment effect, with mean changes favoring high dose in both cUHDRS and TFC at 48 months.
The therapy remains generally well-tolerated, with 17% of high-dose patients experiencing resolved CNS inflammation-related serious adverse events.
FDA accepted 36-month data as primary basis for BLA submission under accelerated approval pathway.

The big picture

uniQure’s data positions ifezuntirgene inilparvovec as a potential first-in-class treatment for Huntington’s disease, a market with no approved disease-modifying therapies. The results come at a time when gene therapies are gaining regulatory and commercial traction, particularly for rare neurodegenerative conditions. The key strategic question is whether uniQure can navigate the regulatory pathway efficiently and establish market dominance before potential competitors emerge.

What we're watching

Regulatory Pathway: Whether the FDA will require additional confirmatory studies despite accelerated approval submission.
Data Interpretation: How the market will weigh the 48-month data against the more statistically significant 36-month results.
Competitive Landscape: The pace at which uniQure can commercialize the therapy if approved, given the lack of current disease-modifying treatments for Huntington’s.